Use of gonadotropin-releasing hormone for hastening ovulation in transitional mares.

The research paper is a study that tests whether the administration of a gonadotropin-releasing hormone (GnRH) analog, as an injection or as a subcutaneous implant, can help induce early ovulation in mares.

Overview

This study aimed at examining the effectiveness of a gonadotropin-releasing hormone (GnRH) agonist in hastening ovulation in mares. Forty-five seasonally anestrous mares were split into three different groups and were subjected to different treatments- GnRH agonist administered via intramuscular (IM) injection, GnRH agonist administered through a subcutaneous (SC) implant, and a control group.

Methodology

• The 45 mares used in the study were assigned to three groups, with 15 mares in each. Group 1, the control group, received no treatment; group 2 received intramuscular injections of the GnRH agonist buserelin, and group 3 was administered the GnRH agonist through a subcutaneous implant.
• On certain days (0, 7, 14, and 21) after the initial injection or implantation, six mares per group had their blood drawn at several intervals.
• The blood samples were analyzed for levels of LH (luteinizing hormone) and FSH (follicle-stimulating hormone). Additionally, progesterone concentration was determined on days 4, 6, and 10 after ovulation.
• In parallel to this, ultrasonography was used to track the size and number of follicles and the occurrence of ovulation in the treated and control mares.

Results and Findings

• It was observed that only mares from groups 2 and 3 (those receiving GnRH agonist administered via injection and implant) ovulated within 30 days of the experiment, with 7 out of 15 and 9 out of 15 mares exhibiting this effect respectively. None of the mares from the control group (Group 1) ovulated during this period.
• The study also found that the sizes of the follicles in mares in group 3 (those receiving the implant) were smaller compared to the control group during the treatment phase.
• The response of LH to GnRH agonist was similar among all three groups at day 0, but was greater in mares from group 3 on days 7 and 14, and in mares from groups 2 and 3 on day 21, when compared to the control group.
• It was also found that LH concentrations remained low in untreated mares compared to GnRH-treated mares. Furthermore, LH concentrations for mares in group 3 that ovulated were significantly higher than those for group 2 mares, while FSH concentrations were similar in both treatment groups prior to ovulation.

Conclusion

The overall conclusion from the study is that the GnRH agonist appears to be a potential tool for inducing early ovulation in mares, either when administered as an injectable or as a subcutaneous implant. The response to GnRH was more profound in the mares that received the treatment as a subcutaneous implant.